AI assistant
GlaxoSmithKline PLC — Director's Dealing 2021
Apr 15, 2021
5262_dirs_2021-04-15_eaa5d58e-8166-4ca2-9f6b-f4537c55eb8a.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information ![]()
RNS Number : 6394V
GlaxoSmithKline PLC
15 April 2021
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 April 2021 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £13.2160 | 10,892.850 |
d)
Aggregated information
Aggregated volume Price
N/A (single transaction)
e)
Date of the transaction
2021-04-12
f)
Place of the transaction
London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHZELFFFZLLBBB